» Articles » PMID: 28438617

Tumor Budding As a Risk Factor for Nodal Metastasis in PT1 Colorectal Cancers: a Meta-analysis

Overview
Journal Hum Pathol
Specialty Pathology
Date 2017 Apr 26
PMID 28438617
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Worldwide, colorectal cancer (CRC) screening programs have significantly increased the detection of submucosal (pT1) adenocarcinoma. Completion surgery may be indicated after endoscopic excision of these potentially metastasizing early cancers. However, the postsurgical prevalence of nodal implants does not exceed 15%, leading to questions concerning the clinical appropriateness of any post-endoscopy surgery. Eastern scientific societies (Japanese Society for Cancer of the Colon-Rectum, in particular) include tumor budding (TB), defined as the presence of isolated single cancer cells or clusters of fewer than 5 cancer cells at the tumor invasive front, among the variables that must be included in histologic reports. In Western countries, however, no authoritative endorsements recommend the inclusion of TB in the histology report because of the heterogeneity of definitions and measurement methods as well as its apparent poor reproducibility. To assess the prognostic value of TB in pT1 CRCs, this meta-analysis evaluated 41 studies involving a total of 10137 patients. We observed a strong association between the presence of TB and risk of nodal metastasis in pT1 CRC. In comparing TB-positive (684/2401; 28.5%) versus TB-negative (557/7736; 7.2%) patients, the prevalence of nodal disease resulted in an odds ratio value of 6.44 (95% confidence interval, 5.26-7.87; P<.0001; I = 30%). This increased risk of regional nodal metastasis was further confirmed after accounting for potential confounders. These results support the priority of histologically reporting TB in any endoscopically removed pT1 CRC to direct more appropriate patient management.

Citing Articles

Risk Factors Associated With Lymph Node Metastasis and Recurrence in Surgical Cases of pT1 Colorectal Cancer.

Sasaki B, Yamada M, Mishima Y, Ohmine T, Tani M, Sato A Cureus. 2024; 16(12):e76333.

PMID: 39734562 PMC: 11682683. DOI: 10.7759/cureus.76333.


Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface.

Haddad T, Bokhorst J, Berger M, Dobbelsteen L, Simmer F, Ciompi F J Transl Med. 2024; 22(1):1090.

PMID: 39623479 PMC: 11610196. DOI: 10.1186/s12967-024-05818-z.


Neoteric Predictors for Lymph Node Metastasis in Early Oral Squamous Cell Carcinoma: Tumor Budding and Worst Pattern of Invasion.

Singh A, Pradhan S, Kannan R, Lakshminarayan A, Kumar K, Shaikh M Indian J Otolaryngol Head Neck Surg. 2024; 76(6):5639-5646.

PMID: 39558984 PMC: 11569069. DOI: 10.1007/s12070-024-05050-7.


Tumor Budding, p53, and DNA Mismatch Repair Markers in Sinonasal Intestinal-Type Adenocarcinoma: A Retrospective Study Supports the Adverse Prognostic Impact of Tumor Budding.

Puccio S, Azzarello G, Maffeis V, Laurino L, Mairani E, Conte F Cancers (Basel). 2024; 16(10).

PMID: 38791973 PMC: 11120584. DOI: 10.3390/cancers16101895.


Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer.

Luo Y, Yan Z, Liu J, Li X, Yang M, Fan J World J Gastroenterol. 2024; 30(2):158-169.

PMID: 38312121 PMC: 10835523. DOI: 10.3748/wjg.v30.i2.158.